Specific cytokine-adsorbing columns have also been developed with significant removal rates of proinflammatory cytokines in animal and human sepsis [63] reflecting benefits of modulation of the cytokine profile. Sepsis is, PD-0332991 purchase however, a complex disease entity where removal of single cytokines has marginal effect on the clinical course, as reflected by the many unsuccessful studies using neutralizing antibodies to specific cytokines. The pattern and degree of the inflammatory response, however, is quite different in LDL apheresis as compared to sepsis. Generally, LDL apheresis columns seem to adsorb many proinflammatory cytokines and to some degree

seem to increase some of the anti-inflammatory cytokines, although there are differences between different LDL apheresis columns and studies vary regarding types of patients included. Furthermore, no studies have addressed how or if changes in pro- and anti-inflammatory cytokine profile in LDL apheresis relate to changes in clinical endpoints. Some data indicate that CRP could play a causative role in the pathogenesis of atherosclerosis [64, 65], but data are conflicting

and a consensus has yet to be established [66, 67]. The JUPITER trial clearly PD0325901 ic50 demonstrated that clinical endpoints were reduced along with reductions in CRP and LDL cholesterol in healthy persons with LDL cholesterol below 3.4 mm and CRP below 2 mg/l before intervention [68]. Puntoni Resveratrol et al. [69] found higher levels of CRP in heFH patients compared with controls, however not significantly so. Kojima et al.

[55] found a significant decrease in CRP when treating hypercholesterolemic patients with LDL apheresis. The findings were reproduced by Kobayashi et al. [58, 59] who treated patients with PAD with LDL apheresis. Herchovici et al. [70] found a significant decrease in CRP during LDL apheresis in hypercholesterolemic patients, with differences observed between the different LDL apheresis systems. Our group also noted a significant decrease in CRP during LDL apheresis in heFH [46]. Thus, it seems that most LDL apheresis treatments reduce the inflammatory marker CRP, a factor that could be of pathogenetic importance in subjects prone to atherosclerosis. Lowering of CRP is associated with lowering of clinical end points [68], but it remains to be proven if reduction of CRP in LDL apheresis relates to reduction in endpoints. Fibrinogen, the precursor of fibrin, is associated with risk for cardiovascular disease [71]. Wang et al. [57] found a significant decrease in fibrinogen during LDL apheresis in patients with CAD, a finding that was confirmed by Kobayashi et al. [59] performing LDL apheresis on patients with peripheral artery disease. Otto et al. [56] found a decrease in fibrinogen levels for two types of LDL apheresis in whole blood. Our group compared three different LDL apheresis techniques and found significant decreases in fibrinogen for all columns [72].